Axis-Shield's new commercialisation phase gets off to a "good start" in 2007
This article was originally published in Clinica
Executive Summary
Anglo-Nordic IVD developer Axis-Shield said it succeeded in achieving "strong underlying growth" for 2007 in the face of a weak dollar and the continued decline in homocysteine revenues.